X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-12-11 | AARD | Aardvark Therapeutics, Inc. | Sun Nelson | CFO | P - Purchase | $14.40 | +3,000 | 108,484 | +3% | +$43,200 | ||||||
2025-12-11 | AARD | Aardvark Therapeutics, Inc. | Lee Tien-Li | CEO, 10% | P - Purchase | $14.49 | +7,000 | 3,025,641 | 0% | +$101,395 | ||||||
2025-12-12 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | See Remarks | P - Purchase | $3.50 | +2,500 | 12,500 | +25% | +$8,750 | ||||||
| M | 2025-12-10 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $1.07 | -82,971 | 2,890,128 | -3% | -$88,587 | |||||
2025-12-10 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale | $9.99 | -11,570 | 80,758 | -13% | -$115,540 | ||||||
2025-12-12 | IMVT | Immunovant, Inc. | Roivant Sciences Ltd. | Dir, 10% | P - Purchase | $21.00 | +16,666,666 | 113,317,007 | +17% | +$349,999,986 | ||||||
| M | 2025-12-10 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $10.04 | -4,000 | 410,818 | -1% | -$40,140 | |||||
| DM | 2025-12-10 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $321.64 | -664 | 223,106 | 0% | -$213,569 | |||||
| D | 2025-12-10 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $552.18 | -24,800 | 842,704 | -3% | -$13,694,158 | |||||
| D | 2025-12-10 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale+OE | $552.15 | -18,650 | 1,111,129 | -2% | -$10,297,573 | |||||
2025-12-11 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $482.98 | -50 | 470 | -10% | -$24,149 | ||||||
| D | 2025-12-11 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $484.67 | -11,000 | 36,781 | -23% | -$5,331,316 | |||||
| DM | 2025-12-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $487.33 | -8,000 | 639,489 | -1% | -$3,898,662 | |||||
| D | 2025-12-11 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.24 | -3,555 | 0 | -100% | -$11,520 | |||||
| M | 2025-12-10 | SXTP | 60 Degrees Pharmaceuticals, Inc. | Dow Geoffrey S | Pres, CEO | P - Purchase | $0.94 | +12,963 | 49,948 | +35% | +$12,204 | |||||
2025-12-11 | FBLG | Fibrobiologics, Inc. | Garcia Ruben A | GC | P - Purchase | $0.34 | +140,000 | 140,000 | New | +$47,600 | ||||||
| DM | 2025-12-09 | PCRX | Pacira Biosciences, Inc. | Cross Shawn | CFO | S - Sale+OE | $25.07 | -25,000 | 56,250 | -31% | -$626,751 | |||||
| D | 2025-12-09 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $20.85 | -200,000 | 1,497,908 | -12% | -$4,170,000 | |||||
| M | 2025-08-21 | GNLX | Genelux Corp | Yu Yong | SVP, Clinical Development | S - Sale | $3.82 | -4,192 | 145,844 | -3% | -$16,032 | |||||
| M | 2025-08-21 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $3.86 | -17,182 | 538,431 | -3% | -$66,370 | |||||
| M | 2025-08-21 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $3.88 | -3,706 | 156,060 | -2% | -$14,361 | |||||
2025-12-09 | IRD | Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | S - Sale | $2.15 | -4,000,000 | 5,492,171 | -42% | -$8,600,000 | ||||||
2025-12-09 | JAZZ | Jazz Pharmaceuticals Plc | Henderson Mary Elizabeth | SVP, Technical Operations | S - Sale | $169.51 | -2,238 | 19,508 | -10% | -$379,366 | ||||||
| D | 2025-12-09 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $12.00 | -18,000 | 0 | -100% | -$216,000 | |||||
| DM | 2025-12-09 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.33 | -1,245 | 0 | -100% | -$4,149 | |||||
| D | 2025-12-09 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, European Commercial | S - Sale+OE | $28.68 | -115,468 | 48,384 | -70% | -$3,311,126 | |||||
| D | 2025-12-09 | TEVA | Teva Pharmaceutical Industries Ltd | Sabag Mark | See "Remarks" | S - Sale+OE | $28.73 | -216,892 | 52,828 | -80% | -$6,230,754 | |||||
2025-12-10 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $36.38 | -3,081 | 95,146 | -3% | -$112,087 | ||||||
| D | 2025-12-09 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale+OE | $12.00 | -34,000 | 48,473 | -41% | -$408,000 | |||||
| D | 2025-12-10 | APRE | Aprea Therapeutics, Inc. | Duey Marc | Dir | P - Purchase | $1.17 | +21,459 | 256,757 | +9% | +$25,000 | |||||
| D | 2025-12-10 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | SrVP, CFO, Prin Fin, Acct Ofcr | P - Purchase | $1.17 | +5,000 | 27,733 | +22% | +$5,825 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Rawcliffe Adrian | Dir | S - Sale+OE | $15.00 | -42,000 | 12,700 | -77% | -$630,000 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Wagner Heidi L | Dir | S - Sale+OE | $13.50 | -14,000 | 44,930 | -24% | -$189,000 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Henry Christian O | Dir | S - Sale+OE | $14.65 | -93,445 | 12,700 | -88% | -$1,369,324 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Tan Aik Na | Dir | S - Sale+OE | $13.58 | -134,218 | 25,400 | -84% | -$1,823,159 | |||||
2025-12-08 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Dir | S - Sale | $13.47 | -20,000 | 275,217 | -7% | -$269,461 | ||||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale+OE | $14.57 | -441,031 | 25,000 | -95% | -$6,427,085 | |||||
| DM | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Moran Kyle | CFO | S - Sale+OE | $15.78 | -260,036 | 90,365 | -74% | -$4,103,979 | |||||
2025-12-08 | WVE | Wave Life Sciences Ltd. | Corrigan Mark | Dir | S - Sale | $13.48 | -16,115 | 28,815 | -36% | -$217,297 | ||||||
2025-12-09 | CRMD | Cormedix Inc. | Lefkowitz Steven W | Dir | S - Sale | $11.88 | -40,000 | 112,650 | -26% | -$475,200 | ||||||
2025-12-08 | XCUR | Exicure, Inc. | Sangsangin Investment & Securities Co., Ltd. | 10% | S - Sale | $8.71 | -433,332 | 0 | -100% | -$3,774,322 | ||||||
2025-12-10 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $6.67 | +746 | 1,141,683 | 0% | +$4,976 | ||||||
| DM | 2025-12-08 | TENX | Tenax Therapeutics, Inc. | Rich Stuart | Chief Medical Officer | P - Purchase | $10.16 | +5,000 | 12,654 | +65% | +$50,793 | |||||
| D | 2025-12-10 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | CFO | P - Purchase | $6.58 | +770 | 742,414 | 0% | +$5,067 | |||||
| D | 2025-11-26 | MRUS | Merus N.V. | Shuman Harry | VP Controller, PAO | S - Sale+OE | $96.10 | -1,700 | 11,002 | -13% | -$163,370 | |||||
2025-12-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $21.02 | -6,663 | 263,311 | -2% | -$140,073 | ||||||
| D | 2025-12-08 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $41.49 | -42,841 | 31,086 | -58% | -$1,777,473 | |||||
| D | 2025-12-09 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | S - Sale+OE | $8.25 | -6,612 | 155,142 | -4% | -$54,575 | |||||
2025-12-09 | UTHR | United Therapeutics Corp | Mesa Nilda | Dir | S - Sale | $481.63 | -187 | 5,286 | -3% | -$90,065 | ||||||
| DM | 2025-12-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $479.17 | -8,000 | 639,489 | -1% | -$3,833,374 | |||||
| DM | 2025-12-08 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | See remarks below, 10% | S - Sale+OE | $8.25 | -6,612 | 155,142 | -4% | -$54,575 | |||||
2025-12-08 | FULC | Fulcrum Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $13.98 | -4,175,139 | 6,053,960 | -41% | -$58,377,021 | ||||||
| D | 2025-12-08 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale+OE | $48.17 | -17,600 | 103,613 | -15% | -$847,855 | |||||
2025-12-08 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale | $110.32 | -7,084 | 54,650 | -11% | -$781,537 | ||||||
| M | 2025-12-08 | MLTX | Moonlake Immunotherapeutics | Santos Da Silva Jorge | CEO | S - Sale | $14.87 | -200,000 | 2,878,577 | -6% | -$2,974,700 | |||||
| M | 2025-12-08 | MLTX | Moonlake Immunotherapeutics | Reich Kristian | Chief Scientific Officer | S - Sale | $14.85 | -202,908 | 2,974,551 | -6% | -$3,012,462 | |||||
2025-12-08 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale | $32.28 | -3,978 | 11,831 | -25% | -$128,411 | ||||||
2025-12-08 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale | $32.27 | -13,430 | 49,124 | -21% | -$433,385 | ||||||
| M | 2025-12-08 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.10 | -4,808 | 61,792 | -7% | -$192,781 | |||||
| D | 2025-12-08 | VERA | Vera Therapeutics, Inc. | Turner William D. | Chief Regulatory Officer | S - Sale+OE | $45.31 | -10,000 | 22,500 | -31% | -$453,053 | |||||
2025-12-09 | KURA | Kura Oncology, Inc. | Hasnain Faheem | Dir | S - Sale | $10.98 | -10,000 | 23,983 | -29% | -$109,764 | ||||||
| DM | 2025-12-08 | GALT | Galectin Therapeutics Inc | Shlevin Harold H. | Dir | S - Sale+OE | $6.00 | -175,790 | 11,206 | -94% | -$1,055,311 | |||||
2025-12-08 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $74.26 | -2,000 | 130,297 | -2% | -$148,520 | ||||||
| M | 2025-08-21 | GNLX | Genelux Corp | Smalling Ralph | Head of Regulatory | S - Sale | $3.75 | -2,332 | 68,658 | -3% | -$8,740 | |||||
| M | 2025-12-05 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | S - Sale | $45.33 | -25,205 | 20,300 | -55% | -$1,142,513 | |||||
2025-12-05 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $9.84 | +186,377 | 5,756,984 | +3% | +$1,833,760 | ||||||
2025-12-09 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale | $28.83 | -10,000 | 178,801 | -5% | -$288,289 | ||||||
| D | 2025-12-08 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $16.51 | -7,294 | 424,520 | -2% | -$120,424 | |||||
2025-12-05 | ANIP | Ani Pharmaceuticals Inc | Tannenbaum Renee P | Dir | S - Sale | $81.15 | -1,800 | 25,157 | -7% | -$146,070 | ||||||
2025-12-05 | ARWR | Arrowhead Pharmaceuticals, Inc. | Perry Michael S | Dir | S - Sale | $61.03 | -16,250 | 115,240 | -12% | -$991,738 | ||||||
| D | 2025-12-05 | EBS | Emergent Biosolutions Inc. | Richard Ronald | Dir | S - Sale+OE | $11.97 | -21,984 | 98,417 | -18% | -$263,077 | |||||
| D | 2025-12-05 | JAZZ | Jazz Pharmaceuticals Plc | Carr Patricia | SVP, Chief Accounting Officer | S - Sale+OE | $171.20 | -4,660 | 7,012 | -40% | -$797,783 | |||||
| M | 2025-12-05 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $1.00 | -95,179 | 2,973,099 | -3% | -$94,787 | |||||
| M | 2025-12-05 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $10.45 | -6,000 | 414,818 | -1% | -$62,720 | |||||
2025-12-05 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.15 | -41,576 | 186,418 | -18% | -$1,627,815 | ||||||
| D | 2025-12-05 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | GC | S - Sale+OE | $40.52 | -10,250 | 0 | -100% | -$415,330 | |||||
| D | 2025-12-08 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $478.60 | -21,000 | 8,142 | -72% | -$10,050,597 | |||||
2025-12-05 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.20 | +13,740 | 1,368,869 | +1% | +$16,441 | ||||||
| M | 2025-12-05 | MRVI | Maravai Lifesciences Holdings, Inc. | Lucier Gregory T | Dir | P - Purchase | $3.69 | +100,000 | 264,907 | +61% | +$368,544 | |||||
| D | 2025-12-08 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $478.58 | -22,500 | 2,648 | -89% | -$10,768,001 | |||||
2025-12-05 | COLL | Collegium Pharmaceutical, Inc | Balice-Gordon Rita J. | Dir | S - Sale | $47.03 | -3,650 | 52,629 | -6% | -$171,673 | ||||||
| M | 2025-12-05 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $39.61 | +744 | 381,708 | 0% | +$29,469 | |||||
| D | 2025-12-05 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | CFO | S - Sale+OE | $39.54 | -20,000 | 0 | -100% | -$790,896 | |||||
2025-12-05 | INSM | Insmed Inc | Sharoky Melvin Md | Dir | S - Sale | $205.01 | -20,000 | 269,796 | -7% | -$4,100,200 | ||||||
2025-12-08 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $4.31 | +45,000 | 2,798,096 | +2% | +$193,794 | ||||||
| D | 2025-12-08 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale+OE | $30.00 | -10,000 | 188,801 | -5% | -$300,000 | |||||
| M | 2025-12-04 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $73.86 | -80,000 | 5,542,909 | -1% | -$5,908,476 | |||||
| D | 2025-12-08 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $65.96 | -1,042 | 50,660 | -2% | -$68,730 | |||||
| M | 2025-11-17 | DMAC | Diamedica Therapeutics Inc. | Stahlberg Jan | 10% | P - Purchase | $7.19 | +1,061,277 | 8,825,742 | +14% | +$7,631,469 | |||||
| M | 2025-12-04 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | S - Sale | $10.93 | -21,295 | 161,359 | -12% | -$232,690 | |||||
| M | 2025-12-04 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | See remarks below, 10% | S - Sale | $10.93 | -21,295 | 161,359 | -12% | -$232,690 | |||||
| DM | 2025-12-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $483.76 | -8,000 | 644,489 | -1% | -$3,870,056 | |||||
2025-12-04 | XOMA | Xoma Royalty Corp | Hughes Owen | CEO | P - Purchase | $25.05 | +100,000 | 200,563 | +99% | +$2,505,000 | ||||||
| D | 2025-12-04 | CBIO | Crescent Biopharma, Inc. | Fairmount Funds Management LLC | Dir, 10% | P - Purchase | $13.41 | +1,360,000 | 2,747,866 | +98% | +$18,237,600 | |||||
2025-12-04 | RNAC | Cartesian Therapeutics, Inc. | Barabe Timothy C | Dir | P - Purchase | $6.86 | +30,000 | 54,366 | +123% | +$205,797 | ||||||
| AM | 2025-12-02 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $5.68 | -162,069 | 5,670,138 | -3% | -$920,855 | |||||
2025-12-05 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.96 | +10,000 | 766,460 | +1% | +$9,600 | ||||||
| DM | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale+OE | $31.19 | -5,358 | 19,798 | -21% | -$167,115 | |||||
| DM | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale+OE | $31.13 | -15,001 | 62,554 | -19% | -$466,959 | |||||
| DM | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale+OE | $31.25 | -9,803 | 15,809 | -38% | -$306,322 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |